Preclinical development and multimodal imaging of novel immunovirotherapeutics for cancer (C07)

溶瘤病毒代表了一类新的癌症治疗药物，因为它们具有选择性地裂解感染肿瘤细胞的内在能力，同时引发有效的抗肿瘤免疫反应，提供持久的全身免疫。我们提出一种新型假疱疹性口炎病毒载体与过继性T细胞治疗相结合作为一种强大的病毒免疫治疗策略。我们将采用多模态和多参数成像来无创监测治疗剂的生物分布和动力学，以及成像局部微环境对治疗反应的特定生物变化，以促进临床翻译和识别反应的预测性生物标志物。

Oncolytic viruses represent a novel class of cancer therapeutics, due to their intrinsic ability to selectively lyse infected tumor cells, while priming potent anti-tumor immune responses to provide lasting systemic immunity. We propose the combination of a novel pseudotyped vesicular stomatitis virus vector with adoptive T cell therapy as a powerful viro-immunotherapeutic strategy. We will employ multimodal and multiparametric imaging to noninvasively monitor the biodistribution and kinetics of the therapeutic agents, as well as to image specific biological changes to the local microenvironment in response to the therapy, in order to facilitate clinical translation and identify predictive biomarkers of response.